Jiate Excelsior

Jiate Excelsior is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the development of novel small molecule drugs for oncology and inflammatory diseases. The company's primary focus is on targeting the MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) protease, a key mediator in the NF-κB signaling pathway. Its lead candidate, JTE-001, is a first-in-class MALT1 inhibitor currently undergoing Phase 1 clinical evaluation for relapsed or refractory B-cell non-Hodgkin lymphoma. Jiate Excelsior aims to address significant unmet medical needs by developing precision medicines that modulate critical immune and oncogenic pathways. The company has successfully obtained IND clearances from both the U.S. FDA and the China NMPA, demonstrating its global development strategy. Backed by prominent venture capital firms, Jiate Excelsior continues to expand its pipeline of small molecule therapeutics targeting high-value biological pathways.